Ozempic maker Novo Nordisk sues US rival over ‘materially misleading’ ads
Danish pharma company says Eli Lilly using outdated trial data to make its weight-loss drugs appear more effectiveOzempic maker Novo Nordisk said Tuesday it is suing arch US rival Eli Lilly over “false and materially misleading” adverts for its competing weight-loss and anti-diabetes treatments.The Danish pharmaceuticals heavyweight complained that the US group – which makes rival weight-loss treatments Zepbound and Mounjaro – “intentionally selected outdated studies” that compared Lilly’s highest doses against lower doses of Novo Nordisk’s medicines.
Reported by 1 outlet — The Guardian US. See all sources ↓
Read the full report at The Guardian US ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
- What's the story?
- Danish pharma company says Eli Lilly using outdated trial data to make its weight-loss drugs appear more effectiveOzempic maker Novo Nordisk said Tuesday it is suing arch US rival Eli Lilly over “false and materially misleading” adverts for its competing weight-loss and anti-diabetes treatments.The Danish pharmaceuticals heavyweight complained that the US group – which makes rival weight-loss treatments Zepbound and Mounjaro – “intentionally selected outdated studies” that compared Lilly’s highest doses against lower doses of Novo Nordisk’s medicines.
- How widely is it covered?
- 1 outlet, average source rating 8.0/10.
- When was it last updated?
- 1h ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Ozempic maker Novo Nordisk sues US rival over ‘materially misleading’ ads
Sources1TypeCoverageThe Guardian US